Device continues to produce vapor [device issue].Received too much medication [incorrect dose administered by device].Lightheadedness.Case description: this case is a spontaneous report from the united states received from a consumer via a specialty pharmacy on 03/02/2016.The patient was a (b)(6), (b)(6), male of unreported height and race, who first received tyvaso (treprostinil) via inhalation route on (b)(6) 2015 for secondary pulmonary hypertension.Inhaled (ih) treprostinil dosage was 18-54 micrograms (3-9 breaths), four times a day, at the time of the events.Inhaled treprostinil was delivered via tyvaso inhalation system, model td-100/a, serial number (b)(4).The patient was on the following concomitant medications at the time of the events: sildenafil and letairis (ambrisentan).On an unspecified date in 2016, the patient's device produced vapor/mist even when the patient was not inhaling, which lead to the patient receiving too much medication.Approximately 30 minutes post treatment, the patient had lightheadedness which lasted for about an hour and then abated.The patient felt much better when he used an alternate device.Patient reports device was continuously producing vapor/mist causing the patient to receive too much drug output.The specialty pharmacy confirmed the devices were replaced.The investigation is incomplete at the time of this report.Mfr name, city and state: (b)(4).Initial reporter: name, address and telephone number withheld.Device manufacture date: 07/2014.Mfr#: (b)(4).
|